The importance of treating tobacco dependence;La importancia de tratar la dependencia tabáquica

Revista Espanola de Cardiologia

Volumn 61, Issue 6, 2008, Pages 620-628

  McRobbie, Hayden ^a   Thornley, Simon ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Auckland Regional Public Health Service   (New Zealand)

Author keywords

Nicotine replacement; Risk factor; Smoking

Indexed keywords

AMFEBUTAMONE; NORTRIPTYLINE; PLACEBO; VARENICLINE;

ACUPUNCTURE; BEHAVIOR THERAPY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; COUNSELING; DRUG EFFICACY; HEALTH CARE FACILITY; HUMAN; NICOTINE REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SMOKING CESSATION; SMOKING HABIT; SUPPORT GROUP; SYMPTOMATOLOGY; TOBACCO DEPENDENCE;

EID: 46449109744     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13123068     Document Type: Review

References (81)

1. Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS, et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation. 2007;115:2621-7.
2. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995;92:1094-100.
3. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol. 2007;5:276-92.
4. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107:973-7.
5. Stewart RA, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, et al. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation. 2005;111:1756-62.
6. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-203.
7. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317:1303-9.
8. Waters D, Lesperance J, Gladstone P, Boccuzzi SJ, Cook T, Hudgin R, et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation. 1996;94:614-21.
9. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. 2006;368:647-58.
10. Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation. 1995;91:1749-56.
11. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005;111:2684-98.
12. Whincup PH, Gilg JA, Emberson JR, Jarvis MJ, Feyerabend C, Bryant A, et al. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ. 2004;329:200-5.
13. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344-53.
14. Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg. 2003;38:329-34.
15. Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, Van Ree JW, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Peripheral Arterial Occlusive Disease. Scand J Prim Health Care. 1998;16:177-82.
16. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81-157.
17. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005;42:67-74.
18. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:1583-633.
19. Hart CL, Hole DJ, Smith GD. Risk factors and 20-year stroke mortality in men and women in the Renfrew/Paisley study in Scotland. Stroke. 1999;30:1999-2007.
20. Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46:11-29.
21. Bjartveit K, Tverdal A. Health consequences of smoking 1-4 cigarettes per day. Tobacco Control. 2005;14:315-20.
22. Negri E, La Vecchia C, Nobili A, D'Avanzo B, Bechi S. Cigarette smoking and acute myocardial infarction. A casecontrol study from the GISSI-2 trial. GISSI-EFRIM Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto - Epidemiologia dei Fattori di Rischio dell'infarto Miocardioco. Eur J Epidemiol. 1994;10:361-6.
23. Haustein K. Tobacco or Health. Berlin: Springer; 2002.
24. Vardulaki KA, Walker NM, Day NE, Duffy SW, Ashton HA, Scott RA. Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. Br J Surg. 2000;87:195-200.
25. Hunter KA, Garlick PJ, Broom I, Anderson SE, McNurlan MA. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci. 2001;100:459-65.
26. Eliasson B, Hjalmarson A, Kruse E, Landfeldt B, Westin A. Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine & Tobacco Research. 2001;3:249-55.
27. Terres W, Becker P, Rosenberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med. 1994;97:242-9.
28. Morita H, Ikeda H, Haramaki N, Eguchi H, Imaizumi T. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J Am Coll Cardiol. 2005;45:589-94.
29. Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med. 2002;137:494-500.
30. Hasdai D, Bell MR, Grill DE, Berger PB, Garratt KN, Rihal CS, et al. Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1005-11.
31. Van Domburg RT, Meeter K, Van Berkel DF, Veldkamp RF, Van Herwerden LA, Bogers AJ. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol. 2000;36:878-83.
32. Robbins AS, Manson JE, Lee IM, Satterfield S, Hennekens CH. Cigarette smoking and stroke in a cohort of U.S. male physicians. Ann Intern Med. 1994;120:458-62.
33. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253-60.
34. Bartecchi C, Alsever RN, Nevin-Woods C, Thomas WM, Estacio RO, Bartelson BB, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation. 2006;114:1490-6.
35. USDHHS. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Rockville: United States Department of Health and Human Services; 1964.
36. Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction. 1994;89:1419-23.
37. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393:295-314.
38. Rose J, Behm F, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug Alcohol Depend. 1999;56:99-107.
39. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system throught the ventral tegmental area. Brain Res. 1994;653:278-84.
40. Corrigall WA, Franklin KJB, Coen KM, Clarke P. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology. 1992;107:285-9.
41. McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res. 2004;6:655-9.
42. Hajek P, Gillison F, McRobbie H. Stopping smoking can cause constipation. Addiction. 2003;98:1563-7.
43. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9:315-27.
44. Etter JF. Comparing the efficacy of two Internet-based, computer-tailored smoking cessation programs: a randomized trial. J Med Internet Res. 2005;7:e2.
45. Shiffman S, Hickcox M, Paty JA, Gnys M, Richards T, Kassel JD. Individual differences in the context of smoking lapse episodes. Addict Behav. 1997;22:797-811.
46. Mabry PL, Tooze JA, Moser RP, Augustson EM, Malcolm RJ, Benowitz NL. Nicotine, cotinine, withdrawal, and craving patterns during smoking and nicotine nasal spray use: results from a pilot study with African American men. Nicotine Tob Res. 2007;9:65-82.
47. Smoking-related behaviour and attitudes, 2006. Newport: Office for National Statistics; 2006.
48. West R, McEwen A. Sex and Smoking: Comparisons between male and female smokers. London: No Smoking day; 1999.
49. West R, Sohal T. "Catastrophic" pathways to smoking cessation: findings from national survey. BMJ. 2006;332:458-60.
50. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6 Suppl 2:S57-62.
51. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34:102-11.
52. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29-38.
53. New Zealand Smoking Cessation Guidelines. Wellington: Ministry of Health; 2007.
54. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000165.
55. Russell MA, Wilson C, Taylor C, Baker CD. Effect of general practitioners' advice against smoking. Br Med J. 1979;2:231-5.
56. McEwen A, West R, McRobbie H. Effectiveness of specialist group treatment for smoking cessation vs. one-to-one treatment in primary care. Addict Behav. 2006;31:1650-60.
57. Judge K, Bauld L, Chesterman J, Ferguson J. The English smoking treatment services: short-term outcomes. Addiction. 2005;100 Suppl 2:46-58.
58. Treating tobacco use and dependence. Rockville: United States Department of Health and Human Services, Agency for Healthcare Research Quality; 2000.
59. Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2006;(3):CD002850.
60. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292.
61. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001007.
62. Hajek P, McRobbie H, Gillison F. Dependence potential of nicotine replacement treatments: Effects of product type, patient characteristics, and cost to user. Prev Med. 2007;44:230-4.
63. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162:1267-76.
64. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database System Rev. 2006;(2).
65. McRobbie H. Zyban: non-nicotine aid to smoking cessation. Prescriber. 2001;12:23-8.
66. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD000031.
67. Aubin H-J. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002;62 Suppl 2:45-52.
68. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary Number 52. London: The Pharmaceutical Press; 2006.
69. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70:801-5.
70. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008;197:371-7.
71. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2007;(1):CD006103.
72. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch Intern Med. 1994;154:989-95.
73. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998;18:297-308.
74. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis. 2003;45:429-41.
75. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction. 2001;96:1547-51.
76. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946-55.
77. McRobbie H, Hajek P, Bullen C, Feigen V. Rapid review of non-NHS treatments for smoking cessation. London: National Institute of Clinical Excellence; 2006.
78. McRobbie H, Thornley S, Lin R, Bullen C, Hajek P, Laugesen M, et al. The effects of three novel nicotine replacement therapies on the relief of tobacco withdrawal symptoms. Portland: Society for Research on Nicotine and Tobacco, 14th Annual Meeting; 2008.
79. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. 2004;9:39-53.
80. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
81. Ussher M. Exercise interventions for smoking cessation. Cochrane Database Syst Rev. 2005;(1):CD002295.